Gene therapy for the treatment of renal disease: Prospects for the future

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 5, 1997, Pages 496-503

  Imai, Enyu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; CHRONIC KIDNEY DISEASE; GENE TARGETING; GENE THERAPY; HUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW;

EID: 0030929058     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199709000-00015     Document Type: Review

References (76)

1. Leiden J: Gene therapy: promise, pitfalls, and prognosis. N Engl J Med 1995, 333:871-873.
2. Crystal G: Transfer of genes to humans: early lessons and obstacles to success. Science 1995, 270:404-411.
3. Harris JD, Lemoine NR: Strategies for targeted gene therapy. Trends in Genetics 1996, 12:400-405.
4. Friedmann T: Human gene therapy: an immature genie, but certainly out of the bottle. Nature Med 1996, 2:144-147.
5. Ross GE, Knorr R, Motulsky D, Parkman AG, Samulski R, Straus J, Smith SE, Smith BR: Gene therapy in the United States: a five-year status report. Hum Gene Ther 1996, 7:1781-1790.
6. Roth JC, Cristiano RJ: Gene therapy for cancer. J Natl Cancer Inst 1997, 89:21-39. The authors reviewed the current status of and future strategies for human gene therapy, and included an appendix of protocols for human gene therapy on cancer.
7. Kitamura M: Transfer of exogenous genes into the kidney. Exp Nephrol 1994, 2:313-317.
8. Riley DJ, Lee W-H: The potential gene therapy for treatment of kidney diseases. Semin Nephrol 1995, 15:57-69.
9. Fine LG: Gene transfer into the kidney: promise for unravelling disease mechanisms, limitations for human gene therapy [editorial]. Kidney Int 1996, 49:612-619. This is a comprehensive review on gene transfer and gene therapy from the view point of the nephrologist.
10. Lipkowitz MK, Bruggeman ME, Nicklin LA, Hanss P, Rappaport J, Klotman PE: Molecular therapy for renal diseases. Am J Kidney Dis 1996, 28:475-492.
11. Isaka Y, Imai E: Molecular biological intervention. Semin Nephrol 1996, 16:591-598.
12. Blaese RM, Culver KW, Chang L, Anderson WF, Mullen C, Nienhuis A, Carter C, Dunber C, Berger M: Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34 + selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195. Hum Gene Ther 1993, 4:521-527.
13. Wivel N: Gene therapy and acquired diseases. Bull Jpn Soc Gene Ther 1997, 3:2-5.
14. Orkin SH, Motulsky AG: Report and recommendations of the panel to assess the investment in research on gene therapy. 1995
15. Naldini L, Blomer U, Gage FH, Trono D, Verma IM: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996, 93:11382-11388.
16. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
17. Yang Y, Li Q, Ertl C, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995, 69:2004-2015.
18. Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 1994, 91:6196-6120.
19. Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC: Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996, 70:4173-4178.
20. Yeh P, Dedieu J-F, Orsini C, Vigne E, Deneffe P, Perricaudet M: Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996, 70:559-565.
21. Fender P, Ruigrok RWH, Gout E, Buffet S, Chroboczek J: Adenovirus dodecahedron, a new vector for human gene transfer. Nature Biotech 1997, 15:52-56.
22. Linden R, Ward P, Giraud C, Winocour E, Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1996, 93:11288-11294.
23. Ponnazhagan S, Erikson D, Kearns WG, Zhou SZ, Nahreini P, Wang X-S, Srivastava A: Lack of site-specific integration of the recombinant adeno-asociated virus 2 genomes in human cells. Hum Gene Ther 1997, 8:275-284.
24. Baudard M, Flotte TR, Aran JM, Thierry AR, Pastan I, Pang M-G, Kearns WG, Gottesman MM: Expression of the human multidrug resistance and glucocerebrosidase cDNA from adeno-associated vectors: efficient promotor activity of AAV sequences and in vivo delivery via liposomes. Hum Gene Ther 1996, 7:1309-1322.
25. Kessler PD, Podsakoff GM, Cher X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ: Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 1996, 93:14082-14087.
26. Ledley F: Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 1995, 6:1129-1144.
27. Yanagihara I, Kaneda Y, Inui K, Okada S: Liposome-mediated gene transfer. In Molecular and Cell Biology of Human Gene Therapeutics. Edited by Dickson G. London: Chapman & Hall; 1995:64-82.
28. Feigner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987, 84:7413-7417.
29. Goyal K, Huang L: Gene therapy using DC-chol liposomes. J Liposome Res 1995, 5:49-60.
30. Wheeler CF, Tsai PL, Marshall YJ, Sukhu J, Don L, Hartikka SG, Nietupski J, Manthorpe J, Nichols M, Plewe M et al.: A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A 1996, 93:11454-11459.
31. Lee EM, Siegel I, Jiang CS, Yew C, Nichols NS, Nietupski MR, Ziegler JB, Lane RJ, Wang MB, Wan KX et al.: Detailed analysis of structure and formations of cationic lipids for efficient gene transfer to the lung. Hum gene Ther 1996, 7:1701-1707.
32. Kaneda Y, Morishita R, Tomita N: Increased expression of DNA cointroduced with nuclear protein in adult rat liver. J Mol Med 1995, 73:289-297.
33. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T et al.: Inhibition of TGF-beta;1 expression by glomerulonephritis. Kidney Int 1996, 50:148-155. This is the first report of application of antisense therapy to experimental glomerulonephritis. Antisense ODN against TGF-β inhibits its expression in the nephritic glomeruli, and the diminution of TGF-β expression was similar to suppression of the ECM expansion.
34. Imai E, Isaka Y, Akagi Y, Kaneda Y: Gene transfer into the glomerulus by the hemagglutinating virus of Japan-liposome method. Exp Nephrol 1997, 5:112-117.
35. Tomita N, Higaki J, Morishita R, Kato K, Mikami H, Kaneda Y, Ogihara T: Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 1992, 186:129-134.
36. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993, 92:2597-2601.
37. Arai M, Wada A, Isaka Y, Akagi Y, Sugiura T, Miyazaki M, Moriyama T, Kaneda Y, Naruse K, Naruse M et al.: In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced enotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 1995, 206:525-532.
38. Heikkila P, Parpala T, Lukkarinen O, Weber M, Tryggvason K: Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system: first steps towards gene therapy of Alport syndrome. Gene Ther 1996, 3:21-27. This is the first report of in-vivo gene transfer using adenovirus vector system. Outstanding efficacy of glomerulus-selective gene transfer was achieved using reno perfusion of adenovirus.
39. Kitamura M, Taylor S, Unwin R, Burton S, Shimizu F, Fine LG: Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplificaton, and sustained expression of an exogenous gene in vivo. J Clin Invest 1994, 94:497-505.
40. Kitamura M: Gene delivery into the glomerulus via mesangial cell vectors. Exp Nephrol 1997, 5:118-125. A newly developed technique that allows selective gene transfer to the glomerulus might provide a device for glomerular engineering.
41. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE: Transport of phosphorothioate oligonucleotides in kidney: implicatons for molecular therapy. Kidney Int 1995, 47:1462-1469.
42. +/Pi cotransporter by ansense oligonucleotides. Proc Natl Acad Sci U S A 1996, 93:4903-4906.
43. Len Y-H H, Lai L-W: Liposome-mediated gene transfer into kidney tubules. Exp Nephrol 1997, 5:132-136.
44. Bosch RJ, Woolf AS, Fine LG. Gene transfer into the mammalian kidney: direct retrovirus transduction of regenerating tubular epithelial cells. Exp Nephrol 1993, 1:49-54.
45. Mouiller P, Friedlander G, Cause D. Ronco P, Perricaudet M, Ferry N: Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int 1994, 45:1220-1225.
46. Zhu G, Nicolson AG, Cowley BD, Rosen S, Sukhatme VP: In vivo adenovirus-mediated gene transfer into normal and cystic rat kidneys. Gene Ther 1996, 3:298-304.
47. Zeigler ST, Kerby JD, Curiel DT, Diethelm AG, Thompson JA: Molecular conjugate-mediated gene transfer into isolated human kidneys. Transplantation 1996, 61:812-817.
48. Kelly VR, Moore KJ: Application of a gene transfer strategy to identify molecules that incite autoimmune kidney injury. Exp Nephrol 1997, 5:144-151.
49. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 1993, 261:1004-1012.
50. Askari FM: Antisense-oligonucleotide therapy. N Engl J Med 1996, 334:316-318. This review outlines the recent concept on antisense therapy and describes its application and limitation in clinical medicine.
51. Wanger R: Gene inhibition using antisense oligodeoxynucleotides. Nature 1994, 372:333-335.
52. Duff JM, Monia BP, Berk BC: Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells. J Biol Chem 1995, 7161-7166.
53. Burgess TF, Ross EF, Bready SL, Qian JV, Bayewitch Y, Cohen LA, Herrera AM, Hu CJ, Kramer SSF, Lott TB et al: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonsense mechanism. Proc Natl Acad Sci U S A 1995, 92:4051-4055.
54. Perez JR, Li Y, Stein CA, Majumder S, van-Oorschot A, Narayanan R: Sequence-independent induction of Sp1 transcription factor activity by phospholothioate oligonucleotides. Proc Natl Acad Sci U S A 1994, 91:5957-5961.
55. Kashihara N, Maeshima Y, Makino H: Therapeutic intervention in glomerulonephritis by oligonucleotides. Exp Nephrol 1997, 5:126-131.
56. Noiri E, Peresleni T, Miller F, Goligorsky MS: In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 1996, 97:2377-2383.
57. Morishita R, Gibbons GH, Horiuchi M., Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995, 92:5855-5859.
58. Dzau VJ, Mann MJ, Morishita R, Kaneda Y: Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci U S A 1996, 93:11421-11425.
59. Miller A: Putting muscle to work for gene therapy. Nature Med 1997, 3:278-279. Skeletal muscle is now highlighted as a tissue to be targeted by gene therapy because the muscle is easily transfected, is abundant and is highly vascularized. After gene transfer the transgene can produce secreted protein stably for long periods.
60. Tripathy SK, Goldwasser E, Lu MM, Barr E, Leiden JM: Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci U S A 1994, 91:11557-11561.
61. Blau HM, Springer ML: Muscle-mediated gene therapy. N Engl J Med 1995, 333:1554-1556.
62. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996, 2:418-423. Overproduction of a TGF-β inhibitor, decorin, in the skeletal muscle by in-vivo gene transfer inhibits ECM expansion. This is the first report of gene therapy for glomerulonephritis.
63. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM: Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997, 3:306-312.
64. Vandenburgh H, Del Tatto M, Shansky J, Lemaire J, Chang A, Payumo F, Lee P, Goodyear A, Raven L: Tissue-engineered skeletal muscle organoids for reversible gene therapy. Hum Gene Ther 1996, 7:2195-2200.
65. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992, 89:5547-5551.
66. Kitamura M: Creation of a reversible on/off-switch for foreign gene activity in the glomerulus: the marriage of mesangial cell vectors with a tetracycline regulatory system. Proc Natl Acad Sci U S A 1996, 93:7387-7391. This is the first report of an application of tetracycline regulatory gene expression system to the mesangial vector system that allows inducible gene expression in the glomerulus.
67. Bohl D, Naffakh N, Heard JM: Long-term control of erythropoietin secretion by deoxycycline in mice transplanted with engineered primary myo-blasts. Nature Med 1997, 3:299-305.
68. No D, Yao T-P, Evans RM: Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A 1996, 93:3346-3351.
69. Delort JP, Capecchi MR: TAXI/UAS: a molecular switch to control expression of genes in vivo. Hum Gene Ther 1996, 7:809-820.
70. Sauer B, Henderson N: Cre-stimulated recommbination at LoxP-containing DNA sequences placed into the mammalian genome. Nucleic Acids Res 1989, 17:147-161.
71. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K: Deleton of a DNA polymerase b gene segment in T cells using cell type-specific gene targeting. Science 1994, 265:103-106.
72. Anton MG, Graham FL: Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J Virol 1995, 69:4600-4606.
73. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sasaki T, Sugano S, Saito I: Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 1995, 23:3816-3821.
74. Kitamura M, Suto TS: Transfer of genetically engineered macrophages into the glomerulus. Kidney Int 1997, 51:1274-1279.
75. Yokoo T, Kitamura M: Gene transfer of interleukin-1 receptor antagonist into the renal glomerulus via a mesangial cell vector. Biochem Biophys Res Commun 1996, 226:883-888.
76. Humes H: Application of gene and cell therapies in the tissue engineering of a bioartificial kidney. Int J Artif Organs 1996, 19:215-217.